| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.06 |
| mRNA | GW843682X | GDSC1000 | pan-cancer | AAC | -0.097 | 0.06 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.06 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.064 | 0.06 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.06 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.07 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.099 | 0.07 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.07 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.066 | 0.07 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | -0.058 | 0.07 |